Budesonide rectal foam - Dr Falk Pharma

Drug Profile

Budesonide rectal foam - Dr Falk Pharma

Alternative Names: AJG511; Budenofalk Foam; Uceris Foam

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Dr Falk Pharma
  • Developer Dr Falk Pharma; EA Pharma; Salix Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis; Ulcerative proctitis
  • Discontinued Proctitis

Most Recent Events

  • 28 Oct 2016 Preregistration for Ulcerative colitis in Japan (Rectal)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Apr 2015 Salix Pharmaceuticals has been acquired by Valeant Pharmaceuticals International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top